Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05360615 | Recruiting | Empagliflozin in Post AKI Stage 2-3

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Sponsor:

Chulalongkorn University

Information provided by (Responsible Party):

Nattachai Srisawat ,M.D.

Brief Summary:

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Condition or disease

Empagliflozin in Post AKI Stage 2-3

Intervention/treatment

Empagliflozin 10 MG

Placebo

Phase

Phase 1

Study Type : Interventional
Estimated Enrollment : 147 participants
Masking : Quadruple
Primary Purpose : Treatment
Official Title : The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Actual Study Start Date : July 1, 2022
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : July 1, 2024
Arm Intervention/treatment

Experimental: Empagliflozin

Drug: Empagliflozin 10 MG

Placebo Comparator: Placebo

Drug: Placebo
Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • post AKI stage 2-3
  • CrCl > 20
Exclusion Criteria
  • pregnancy
  • post kidney transplant
  • previous use of SGLT2 Inhibitors
  • history of ketoacidosis
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Location Details

Please Choose a site

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

Thailand, Mueang Nonthaburi District

Central Chest Institute of Thailand

Nonthaburi, Mueang Nonthaburi District, Thailand, 11000